# Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

> **NCT00981903** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 131 (actual)

## Conditions studied

- Venous Thromboembolism
- Cancer

## Interventions

- **DRUG:** Tinzaparin sodium

## Key facts

- **NCT ID:** NCT00981903
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2012-10
- **Final completion:** 2015-10
- **Target enrollment:** 131 (ACTUAL)
- **Why stopped:** Tinzaparin will no longer be available in the United States
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981903, "Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00981903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*